How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/familial-x-linked-hypophosphatemic-vitamin-d-refractory-rickets.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Familial x-linked hypophosphatemic vitamin D refractory rickets — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Familial x-linked hypophosphatemic vitamin D refractory rickets (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Familial x-linked hypophosphatemic vitamin D refractory rickets, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Crysvita	BUROSUMAB	Ultragenyx Pharm Inc		FGF23	2018-01-01
Drisdol	ERGOCALCIFEROL	Esjay Pharma	Provitamin D2 Compound [EPC]	25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial	1941-01-01
CRYSVITA	BUROSUMAB-TWZA	KYOWA KIRIN		Fibroblast growth factor 23
Calciferol	Calciferol	Department of Medical Services Ministry of Public Health of Thailand		Vitamin D 25-hydroxylase, 25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial, Vitamin D3 receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Department of Medical Services Ministry of Public Health of Thailand · 1 drug in Familial x-linked hypophosphatemic vitamin D refractory rickets
Esjay Pharma · 1 drug in Familial x-linked hypophosphatemic vitamin D refractory rickets
KYOWA KIRIN · 1 drug in Familial x-linked hypophosphatemic vitamin D refractory rickets
Ultragenyx Pharm Inc · 1 drug in Familial x-linked hypophosphatemic vitamin D refractory rickets

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Familial x-linked hypophosphatemic vitamin D refractory rickets:

Cite this brief

Drug Landscape (2026). Familial x-linked hypophosphatemic vitamin D refractory rickets — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/familial-x-linked-hypophosphatemic-vitamin-d-refractory-rickets. Accessed 2026-06-09.

Familial x-linked hypophosphatemic vitamin D refractory rickets full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing